Biosearch Life (Madrid, Spain), a leading biotechnology company in the world of healthy ingredients, and By-Health (Zhuhai city, China) strengthen their business relationships thanks to the signing of an R&D agreement and a new contract for the supply of isolated strains from breast milk from the Hereditum® range, aimed at child care.
BY-Health, a company that mainly focuses on the research, development, production and distribution of Vitamin & Dietary Supplements, has a market share of 9.2% and has been considered the leading company in its sector in China since its beginning in 1995. By-Health is a markedly transparent company in the performance of its activities at an international level, with strict quality controls throughout the entire value chain. Furthermore, it is also a committed company, collaborating on different projects with internationally renowned organizations.
In the Memorandum of Understanding (MOU) in R&D signed by both companies in May, a commitment was made to collaborate in the development of applications from probiotic strains isolated from breast milk, mainly focused on children’s health. The starting point of the agreement is to facilitate the competitive advantages of the signatory parties in terms of scientific research, technology, product development and marketing, specifically for the Chinese, New Zealand and Australian markets, without prejudice to the possibility of extending into other areas of interest.
These probiotic strains from Biosearch Life’s Hereditum® range have been selected from hundreds of isolated strains obtained from breast milk for their excellent capabilities and proven beneficial effects in children, preventing common childhood infections. The efficacy and safety of both strains has been demonstrated through several clinical trials.
Likewise, the LC40® strain is among the 10 probiotic strains registered in China for use in infant formula. The infant formula market in China is immense, as it is one of the countries with the lowest rate of breastfeeding in the world (around 20%, compared to the global average of 41%).
The child nutrition market in China is the largest in the world; it has become the great engine for growth of the industry worldwide and with great prospects for further growth. The collaboration agreements with the leading company By-Health represent a boost and an opportunity for Biosearch Life to continue growing and developing in this market.
José María Roset, CEO of Biosearch Life, pointed out: “For Biosearch it is very important to be able to count on collaborators at the level of By-Health in such a demanding and, at the same time, promising market as the Asian market, in particular the Chinese. We are convinced that this new trade, business and research relationship, will be very positive for both parties”.